Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study

No abstract is available for this paper.

• Publication year

  2011

• Venue

  British Journal of Haematology

• Publication date

  2011-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1365-2141.2011.08664.xPMID 21534941
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Global cancer statistics

  2011cited by this paper
• A systematic approach to the management of patients with brain metastases of known or unknown primary site

  2011cited by this paper
• Tanespimycin pharmacokinetics: a randomized dose-escalation crossover phase 1 study of two formulations

  2011cited by this paper
• Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose‐escalation study

  2010cited by this paper
• Tanespimycin Reverses Bortezomib-Induced Inhibition of Granulopoiesis.

  2009cited by this paper
• A Systems Biology Approach to Study the Acquisition of Adult Repopulating Potential During Hematopoietic Stem Cell Ontogeny.

  2009cited by this paper
• Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma

  2008cited by this paper
• 152 POSTER Prevention and treatment of bortezomib-induced peripheral neuropathy by the Hsp90 inhibitor tanespimycin (KOS-953) in the rat

  2008cited by this paper
• Improved survival in multiple myeloma and the impact of novel therapies.

  2008cited by this paper
• Clinically relevant end points and new drug approvals for myeloma

  2008cited by this paper
• Cancer Statistics, 2007

  2007cited by this paper
• Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells.

  2007cited by this paper
• Heat shock proteins and neuroprotection.

  2007cited by this paper
• Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.

  2007cited by this paper
• Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.

  2007cited by this paper
• Phase I Pharmacokinetic and Pharmacodynamic Study of 17-N-Allylamino-17-Demethoxygeldanamycin in Pediatric Patients with Recurrent or Refractory Solid Tumors: A Pediatric Oncology Experimental Therapeutics Investigators Consortium Study

  2007cited by this paper
• Phase I and Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin in Adult Patients with Refractory Advanced Cancers

  2007cited by this paper
• Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer

  2007cited by this paper
• New drugs for myeloma.

  2007cited by this paper
• Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.

  2007cited by this paper
• A Phase I Trial of Twice-Weekly 17-Allylamino-Demethoxy-Geldanamycin in Patients with Advanced Cancer

  2006cited by this paper
• Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma

  2006influential reference
• Preliminary Results of a Prospective Randomized Study Comparing First Line Conventional Therapy Versus High Dose Therapy with Autologous CD34+ Purified Progenitor Cell Support in B CLL Patients with B and C Binet Stages: The GOELAMS LLC98 Study.

  2005cited by this paper
• Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies.

  2005cited by this paper
• Global Cancer Statistics, 2002

  2005cited by this paper
• Antimyeloma activity of heat shock protein-90 inhibition.

  2005cited by this paper
• HSP90 and the chaperoning of cancer

  2005cited by this paper
• Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors.

  2005cited by this paper
• Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

  2005cited by this paper
• Safety and Activity of KOS-953 in Patients with Relapsed Refractory Multiple Myeloma (MM): Interim Results of a Phase 1 Trial.

  2005influential reference
• Drug therapy: Multiple myeloma

  2004cited by this paper
• A phase 2 study of bortezomib in relapsed, refractory myeloma.

  2003cited by this paper
• Heat shock proteins and neuroprotection.

  2002cited by this paper
• Multiple myeloma

  2001cited by this paper
• Proteasome inhibition measurements: clinical application.

  2000cited by this paper
• CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION

  1998cited by this paper
• A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.

  1996cited by this paper
• A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma

  1996cited by this paper
• Phase I Trial

  1983cited by this paper
• Multiple myeloma.

  1948cited by this paper

• Therapeutic Targeting of Hypoxia-Inducible Factors in Cancer

  2024cites this paper
• Different Strategies to Overcome Resistance to Proteasome Inhibitors—A Summary 20 Years after Their Introduction

  2024cites this paper
• Combination therapy with HSP90 inhibitors and piperlongumine promotes ROS-mediated ER stress in colon cancer cells

  2023cites this paper
• Novel NRF2‐activated cancer treatments utilizing synthetic lethality

  2022cites this paper
• Targeting Heat-Shock Protein 90 in Cancer: An Update on Combination Therapy

  2022cites this paper
• Hypoxia-Inducible Factor-1: A Novel Therapeutic Target for the Management of Cancer, Drug Resistance, and Cancer-Related Pain

  2022cites this paper
• secDrug: a pipeline to discover novel drug combinations to kill drug-resistant multiple myeloma cells using a greedy set cover algorithm and single-cell multi-omics

  2022cites this paper
• Heat shock proteins: Biological functions, pathological roles, and therapeutic opportunities

  2022cites this paper
• Chaperone-assisted E3 ligase CHIP: A double agent in cancer

  2021cites this paper
• Overview of Ferroptosis and Synthetic Lethality Strategies

  2021cites this paper
• Geldanamycin-Derived HSP90 Inhibitors Are Synthetic Lethal with NRF2

  2020cites this paper
• A molecular basis for the synergy between 17‑allylamino‑17‑demethoxy geldanamycin with Capecitabine and Irinotecan in human colorectal cancer cells through VEFG and MMP-9 gene expression.

  2019cites this paper
• Understanding the binding interaction in therapeutic prevention of inflammation by controlling Hsp90 through curcumin and epigallocatechin

  2019cites this paper
• Role of HSP90 Inhibitors in the Treatment of Cancer

  2019cites this paper
• Bortezomib promotes apoptosis of multiple myeloma cells by regulating HSP27.

  2019cites this paper
• Understanding the binding interaction in therapeutic prevention of inflammation by controlling Hsp90 through curcumin and epigallocatechin

  2019cites this paper
• HSP90 Inhibitors Blocking Multiple Oncogenic Signaling Pathways for the Treatment of Cancer

  2019cites this paper
• Targeting Proteotoxic Stress in Cancer: A Review of the Role that Protein Quality Control Pathways Play in Oncogenesis

  2019influential citation
• Spotlight on 17‐AAG as an Hsp90 inhibitor for molecular targeted cancer treatment

  2019cites this paper
• Targeting Heat Shock Proteins in Multiple Myeloma

  2019cites this paper
• Traditional and Novel Mechanisms of Heat Shock Protein 90 (HSP90) Inhibition in Cancer Chemotherapy Including HSP90 Cleavage

  2019cites this paper
• The effects of bortezomib on the ovariectomy applied rat uterus: A histopathological, stereological, and immunohistochemical study

  2018cites this paper
• HSF1 Is Essential for Myeloma Cell Survival and A Promising Therapeutic Target

  2018influential citation
• Heat shock protein-guided dual-mode CT/MR imaging of orthotopic hepatocellular carcinoma tumor.

  2018cites this paper
• Therapeutic Targets and Signaling Pathways for Diagnosis of Myeloma

  2018cites this paper
• A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma

  2017influential citation
• Physiopathologie du lymphome à cellules du manteau : de la mécanistique aux modèles précliniques

  2017cites this paper
• Activity of Human T Lymphocytes and NK Regulation of Phenotype and Functional Heat Shock Protein 90 Is Critical for

  2017cites this paper
• Targeting Protein Synthesis, Folding, and Degradation Pathways in Cancer

  2017cites this paper
• A lowered 26S proteasome activity correlates with mantle lymphoma cell lines resistance to genotoxic stress

  2017cites this paper
• Chapter 2 Resistance to Proteasome Inhibitors in Multiple Myeloma

  2017cites this paper
• In vitro study comparing the efficacy of the water-soluble HSP90 inhibitors, 17-AEPGA and 17-DMAG, with that of the non‑water-soluble HSP90 inhibitor, 17-AAG, in breast cancer cell lines.

  2016cites this paper
• Immunoproteasome-Selective Inhibitors: A Promising Strategy to Treat Hematologic Malignancies, Autoimmune and Inflammatory Diseases.

  2016cites this paper
• Reprogramming of Molecular Switching Events in UPR Driven ER Stress: Scope for Development of Anticancer Therapeutics.

  2016cites this paper
• The Role of Intracellular Signaling Pathways in the Pathogenesis of Multiple Myeloma and Novel Therapeutic Approaches.

  2016cites this paper
• Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma

  2016cites this paper
• Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90-Kinase Interactions.

  2016cites this paper
• Determining mechanisms of sensitivity and resistance to HSP90 inhibition in non-small cell lung cancer

  2016cites this paper
• SIRT 1 Inhibitor Enhances Hsp 90 Inhibitor-mediated Abrogation of Hsp 90 Chaperone Function and Potentiates the Cytotoxicity of Hsp 90 Inhibitor in Chemo-resistant Human Cancer Cells

  2016cites this paper
• SIRT1 Inhibitor Enhances Hsp90 Inhibitor-mediated Abrogation of Hsp90 Chaperone Function and Potentiates the Cytotoxicity of Hsp90 Inhibitor in Chemo-resistant Human Cancer Cells

  2016cites this paper
• Novel Tetrahydropyrido[4,3-d]pyrimidines as Potent Inhibitors of Chaperone Heat Shock Protein 90.

  2016cites this paper
• Ganetespib: research and clinical development

  2015cites this paper
• Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma

  2015cites this paper
• Misfolded Proteins: From Little Villains to Little Helpers in the Fight Against Cancer

  2015cites this paper
• Localization of heat shock protein 110 in canine mammary gland tumors.

  2015cites this paper
• Sensitization of multidrug-resistant human cancer cells to Hsp90 inhibitors by down-regulation of SIRT1

  2015cites this paper
• Current treatment landscape for relapsed and/or refractory multiple myeloma

  2015cites this paper
• NKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma

  2015cites this paper
• The 26S proteasome is a multifaceted target for anti-cancer therapies

  2015cites this paper
• Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours.

  2014cites this paper
• Molecularly Targeted Therapies in Multiple Myeloma

  2014cites this paper
• Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma.

  2014cites this paper
• New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)

  2014cites this paper
• Heat shock proteins in multiple myeloma

  2014cites this paper
• Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions

  2014cites this paper
• Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic

  2014cites this paper
• Novel targeted agents in the treatment of multiple myeloma.

  2014cites this paper
• Beyond BRAF: where next for melanoma therapy?

  2014cites this paper
• Evaluating Melanoma Drug Response and Therapeutic Escape with Quantitative Proteomics*

  2014cites this paper
• Change or die: targeting adaptive signaling to kinase inhibition in cancer cells.

  2014cites this paper
• Identification of potential pathways involved in the induction of cell cycle arrest and apoptosis by a new 4-arylidene curcumin analogue T63 in lung cancer cells: a comparative proteomic analysis.

  2014cites this paper
• Novel agents and new therapeutic approaches for treatment of multiple myeloma.

  2014cites this paper
• Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients

  2014cites this paper
• [New drugs in the treatment of multiple myeloma].

  2014cites this paper
• Molecular‐targeted agents combination therapy for cancer: Developments and potentials

  2014cites this paper
• Resistance to Proteasome Inhibitors in Multiple Myeloma

  2014cites this paper
• Angiogenesis Inhibition in Castration-Resistant Prostate Cancer

  2014cites this paper
• Proteasome Inhibitors and Lessons Learned from Their Mechanisms of Action and Resistance in Human Cancer

  2014cites this paper
• New Agents for Multiple Myeloma

  2014cites this paper
• Heat shock response and exercise-induced muscle damage: effects of 17-AAG and glutamine as pharmaceutical inducers of HSPs

  2014cites this paper
• WITHAFERIN A: A NOVEL THERAPEUTIC APPROACH FOR MALIGANT BRAIN TUMORS

  2014cites this paper
• Exploiting Cancer Dependence on Molecular Chaperones: HSP90 Inhibitors Past, Present, and Future

  2014cites this paper
• Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (review).

  2014cites this paper
• Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models

  2014cites this paper
• The Cancer Super-Chaperone Hsp90: Its Posttranslational Regulation and Drug Targeting

  2013cites this paper
• Tanespimycin and Tipifarnib Exhibit Synergism in Inducing Apoptosis in Melanoma Cell Lines From Later Stages of Tumor Progression

  2013cites this paper
• Stressing the Development of Small Molecules Targeting HSP90

  2013cites this paper
• Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia

  2013cites this paper
• Targeting HSP90 and monoclonal protein trafficking modulates the unfolded protein response, chaperone regulation and apoptosis in myeloma cells

  2013cites this paper
• Three Weeks of a Four Week Course or Twice Weekly for Four Weeks of a Four Week Course to Patients with Advanced Solid Tumors

  2013cites this paper
• Endoplasmic Reticulum Stress and the Unfolded Protein Response: Targeting the Achilles Heel of Multiple Myeloma

  2013cites this paper
• Heat Shock Protein 90 Is Critical for Regulation of Phenotype and Functional Activity of Human T Lymphocytes and NK Cells

  2013cites this paper
• Novel Agents in Multiple Myeloma

  2013cites this paper
• Aryl Hydrocarbon Receptor is a Target of 17-Allylamino-17-demethoxygeldanamycin and Enhances its Anticancer Activity in Lung Adenocarcinoma Cells

  2013cites this paper
• Drug combinations with proteasome inhibitors in antitumor therapy.

  2013cites this paper
• The heat shock transcription factor 1 as a potential new therapeutic target in multiple myeloma

  2013cites this paper
• CK2 as a Logical Target in Cancer Therapy: Potential for Combining CK2 Inhibitors with Various Classes of Cancer Therapeutic Agents

  2013cites this paper
• Network Analysis Identifies an HSP90-Central Hub Susceptible in Ovarian Cancer

  2013cites this paper
• Dissecting bortezomib: development, application, adverse effects and future direction.

  2013cites this paper
• Pharmacological targeting of endoplasmic reticulum stress signaling in cancer.

  2013cites this paper
• Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions.

  2013cites this paper
• A Phase 1, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of BIIB021 Administered Orally in Patients with Advanced Solid Tumors

  2013cites this paper
• CellsActivity of Human T Lymphocytes and NK Regulation of Phenotype and Functional Heat Shock Protein 90 Is Critical for

  2013cites this paper
• Inhibition of HSP90 molecular chaperones: moving into the clinic.

  2013cites this paper
• Chemotherapy-Induced Peripheral Neuropathy: Review of Clinical Studies

  2012cites this paper
• Heat shock proteins in hematopoietic malignancies.

  2012cites this paper
• Proteasome inhibitors: introduction.

  2012cites this paper
• Bortezomib combination therapy in multiple myeloma.

  2012cites this paper
• Preclinical activity of the novel orally bioavailable HSP90 inhibitor NVP-HSP990 against multiple myeloma cells.

  2012cites this paper
• Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma

  2012cites this paper